VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, seeking to generate more clinically informative preclinical data while reducing the number of animals required for drug development. The Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays, computational modeling and other human-relevant systems.
The strategy supports development of the company’s BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer. According to the company, new three-dimensional spheroid data reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. The announcement matters because it signals a potential shift in how early-stage cancer drugs are evaluated, aligning preclinical research more closely with human biology while addressing ethical and efficiency concerns around animal testing.
In one example, an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. For investors and industry observers, the move could improve the predictive value of preclinical data and reduce the time and cost associated with traditional animal-heavy studies.
VERAXA’s approach is aligned with FDA guidance on NAMs, which regulators have increasingly encouraged as a way to bring more human-relevant data into drug development. The company’s pipeline focuses on antibody-based therapies designed to engage the immune system against tumors, a crowded but high-value area of oncology research. By adopting NAMs across its programs, VERAXA aims to differentiate its preclinical package and potentially accelerate decision-making on which candidates advance.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. The announcement was distributed with support from MissionIR, a communications platform focused on syndicated content for private and public companies. MissionIR is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to more than 5,000 outlets and other corporate communications services.
For VERAXA, the expanded testing strategy comes as drug developers face growing pressure to demonstrate that preclinical results translate to patients. The company’s claim that its lead candidate produced potent tumor-cell killing across multiple patient-derived models, with minimal activity in controls, offers an early signal of specificity. Whether the NAMs approach yields faster or more reliable clinical outcomes will depend on further validation, but the announcement positions VERAXA among a growing group of biotechs betting on human-relevant models to sharpen oncology drug development.
